Enliven Therapeutics, Inc. (ELVN) Form 8-K — Oct 14, 2026
Enliven Therapeutics appointed Kristine Ball to its board of directors on October 14, 2026, expanding the board from seven to eight members and naming her to the Audit Committee. Ms. Ball brings over 20 years of biopharma executive experience, including CEO roles at Antiva Biosciences and Soteria Biotherapeutics and CFO roles at Menlo Therapeutics and Relypsa, where she helped guide the clinical-to-commercial transition. The appointment comes as Enliven prepares to initiate its pivotal Phase 3 ENABLE-2 trial of relcobatinib in previously treated chronic myeloid leukemia patients before year-end 2026, following recent FDA alignment on the trial design.
Key figures
- Board size
- expanded from seven to eight directors
- Option grant fair value
- $650,000
- Director cash compensation
- $45,000/year plus $10,000/year for Audit Committee service
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.